tiprankstipranks
Trending News
More News >
Oncolys BioPharma, Inc. (JP:4588)
:4588
Japanese Market

Oncolys BioPharma, Inc. (4588) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Oncolys BioPharma, Inc.

(4588)

Rating:45Neutral
Price Target:
¥579.00
▼(-3.18%Downside)
Oncolys BioPharma, Inc. is facing significant financial challenges with declining revenues and persistent losses. Despite a strong equity position, the inability to generate positive cash flow and achieve profitability is a major risk. Technical analysis provides mixed signals, while valuation is weak due to negative earnings and no dividend yield.

Oncolys BioPharma, Inc. (4588) vs. iShares MSCI Japan ETF (EWJ)

Oncolys BioPharma, Inc. Business Overview & Revenue Model

Company DescriptionOncolys BioPharma, Inc. is a Japan-based biotechnology company focused on the development and commercialization of innovative therapeutics for oncology and infectious diseases. The company leverages its proprietary technology platforms to develop novel oncolytic viruses and antiviral agents, aiming to provide cutting-edge treatment options for patients. Oncolys BioPharma's core products include investigational drugs that are in various stages of clinical development.
How the Company Makes MoneyOncolys BioPharma, Inc. generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company earns income through licensing agreements with pharmaceutical partners, which may include upfront payments, milestone payments, and royalties on sales of successfully commercialized products. Additionally, Oncolys may receive research and development funding from collaborations with other biotech and pharmaceutical companies. Strategic partnerships are a significant factor in the company's revenue generation, allowing it to leverage the expertise and resources of larger organizations to advance its drug candidates through clinical trials and into the market.

Oncolys BioPharma, Inc. Financial Statement Overview

Summary
Oncolys BioPharma, Inc. faces serious financial challenges characterized by declining revenues, persistent losses, and negative cash flows. The balance sheet shows strong equity, but the inability to achieve profitability and positive cash flow poses significant risks to long-term viability.
Income Statement
20
Very Negative
Oncolys BioPharma, Inc. has experienced significant revenue decline, with a drop from 2022 to 2023 and further to 2024. The company has consistently operated at a loss, with negative EBIT and net income margins, reflecting challenges in scaling profitable operations.
Balance Sheet
30
Negative
The company maintains a healthy equity position with a strong equity ratio, indicative of solid capitalization. However, the continued losses affect return on equity negatively. While debt levels are manageable, the lack of profitability is concerning for long-term stability.
Cash Flow
25
Negative
Operating and free cash flow have remained negative, indicating ongoing operational cash burn. Despite positive financing cash flow, likely from fundraising, the inability to generate positive cash flow from operations is a critical risk.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue31.38M63.04M976.18M642.49M314.18M
Gross Profit31.38M30.61M338.49M198.80M236.11M
EBITDA-1.68B-1.93B-1.14B-1.60B-2.08B
Net Income-1.68B-1.94B-1.15B-1.62B-2.10B
Balance Sheet
Total Assets3.20B2.04B2.65B4.29B2.80B
Cash, Cash Equivalents and Short-Term Investments2.41B1.53B1.71B3.45B2.07B
Total Debt324.64M315.17M393.66M503.47M525.08M
Total Liabilities446.65M566.50M491.69M697.88M793.09M
Stockholders Equity2.75B1.47B2.16B3.59B2.00B
Cash Flow
Free Cash Flow-2.02B-1.34B-1.72B-1.74B-1.47B
Operating Cash Flow-2.02B-1.34B-1.72B-1.74B-1.47B
Investing Cash Flow-4.71M-5.39M20.12M-942.00K-37.58M
Financing Cash Flow2.88B1.14B-113.83M3.09B242.26M

Oncolys BioPharma, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price598.00
Price Trends
50DMA
589.44
Positive
100DMA
612.37
Negative
200DMA
608.97
Negative
Market Momentum
MACD
3.46
Positive
RSI
47.72
Neutral
STOCH
21.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Negative. The current price of 598 is below the 20-day moving average (MA) of 621.35, above the 50-day MA of 589.44, and below the 200-day MA of 608.97, indicating a neutral trend. The MACD of 3.46 indicates Positive momentum. The RSI at 47.72 is Neutral, neither overbought nor oversold. The STOCH value of 21.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4588.

Oncolys BioPharma, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
¥13.42B284.55
0.74%-13.57%-106.11%
56
Neutral
¥13.31B
256.62%81.71%
54
Neutral
¥12.86B
57.13%-66.39%
52
Neutral
$7.50B0.31-61.87%2.27%17.10%1.59%
48
Neutral
¥9.60B
14.41%27.42%
47
Neutral
¥18.89B
-100.00%-1079.89%
45
Neutral
¥14.91B
11.93%15.04%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4588
Oncolys BioPharma, Inc.
605.00
36.00
6.33%
JP:4579
RaQualia Pharma Inc.
527.00
-72.00
-12.02%
JP:4583
Chiome Bioscience Inc.
141.00
21.00
17.50%
JP:4599
StemRIM Inc.
306.00
-115.00
-27.32%
JP:4880
CellSource Co., Ltd.
672.00
-711.15
-51.42%
JP:4888
STELLA PHARMA CORPORATION
395.00
-49.00
-11.04%

Oncolys BioPharma, Inc. Corporate Events

Oncolys BioPharma Reports Decline in Q1 2025 Financial Results
May 9, 2025

Oncolys BioPharma Inc. reported its financial results for the first quarter of 2025, showing a significant decline in net sales and profits compared to the previous year. The company’s financial position weakened, with total assets and equity ratio decreasing, reflecting challenges in maintaining profitability and market stability.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 03, 2025